ENGENEIC (PTY) LTD.
EnGeneIC is a clinical stage biopharmaceutical company advancing its proprietary bacterially-derived EDV™ nanocells as a powerful nanoparticle drug, siRNA, or miRNA delivery platform designed to directly target and effectively kill tumor cells with minimal toxicity, while simultaneously stimulating the immune system's innate and adaptive anti-tumor response. First- and second-generation EDV™ nanocells have shown promising results in early clinical studies and EnGeneIC is currently planning to commence further clinical trials in several cancer indications in Australia and USA.
Company Email ：admin@engeneic.com
Industry ：BiotechnologyManufacturing GeneralManufacturing
Company address ：New York
Company website ：*****
Company phone ：(866) 808-6088
Established ：2000-01-01
Company Revenue ：$5,152,000
Number of employees ：11-50
SIC Code ：28283
NAICS Code ：54541
Company News
EnGeneIC publishes the COVID-EDV vaccine’s novel mechanism of action in a leading Immunology journal
Jan 31, 2023
SYDNEY, Australia and NEW YORK, Jan. 31, 2023 (GLOBE NEWSWIRE) -- The completely unique mechanism of action of the world’s first COVID-19 vaccine to stimulate “high affinity” antibodies which neutralise most COVID variants has been published by EnGeneIC in the prestigious journal, Frontiers in Immunology (27th January, 2023). This paper illustrates that the COVID-EDV vaccine is a fundamental change in thinking on how to produce an effective and inexpensive vaccine and has broad-reaching ramifica
Jan 31, 2023
Australian biotech, EnGeneIC, develops world-first nanocellular anti-COVID-19 vaccine that defeats mutant viruses and stimulates a broad anti-viral responseSep 8, 2021
SYDNEY and NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- EnGeneIC Limited, an Australian, Sydney-based biotechnology company, has developed a globally unique nanocellular technology that in pre-clinical animal studies has been shown to stimulate a broad and powerful anti-COVID-19 immune response and also neutralises the known mutant COVID-19 viruses of concern, particularly the delta variant.
Sep 8, 2021EnGeneIC Announces Acceptance of Abstract to the Annual Meeting of the American Society of Clinical Oncology 2020Jun 1, 2020
EnGeneIC Limited, a clinical-stage biopharmaceutical company advancing its proprietary EDV™ nanocell platform for targeted cyto-immunotherapy in cancer, today announced that an abstract on the Phase I/IIa clinical trial with EGFR-targeted EDV nanocells in patients with recurrent, metastatic pancreatic cancer has been accepted at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, which will be held from May 29-31, 2020.
Jun 1, 2020EnGeneIC Announces Publication in Cancer Cell of a Scientific Paper Highlighting the Ability of EDV™ Nanocells to Mount Dual Assault on Cancer CellsMar 16, 2020
NEW YORK and SYDNEY, March 16, 2020 /PRNewswire/ -- EnGeneIC Limited, a clinical-stage biopharmaceutical company advancing its proprietary EDV™ nanocell platform for targeted cyto-immunotherapy in cancer, today announced that the prestigious peer-reviewed journal Cancer Cell has published...
Mar 16, 2020EnGeneIC Novel Oncology-Focused Nanotechnology Featured in InsightsCareFeb 12, 2020
EnGeneIC Limited, a clinical-stage biopharmaceutical company advancing its proprietary EDV™ nanocell platform for targeted cyto-immunotherapy in cancer, today announced that the Company was featured in the publication InsightsCare as one of the 10 most innovative healthcare nanotech companies to watch. The December 2019 Issue (Vol 12) describes the convergence of nanotechnology and medicine and shines a spotlight on pioneering companies using nanotech to drive healthcare innovations.
Feb 12, 2020Web Summary
Q1: What is the address of EnGeneIC's Sydney office?
A1: The address of EnGeneIC's Sydney office is Level 4, Building 53, 11 Julius Avenue, North Ryde, NSW Australia 2113.
Q2: What type of products does EnGeneIC develop and manufacture?
A2: EnGeneIC develops and manufactures targeted anti-cancer therapies using its proprietary EDV nanocell platform for the delivery of chemotherapeutics and functional nucleic acids in cancer.
Q3: In which industry is EnGeneIC primarily involved?
A3: EnGeneIC is primarily involved in the biopharmaceutical industry, specifically focused on developing treatments for cancer.
Q4: What services does EnGeneIC offer?
A4: While the provided text does not explicitly state all services offered by EnGeneIC, it mentions that they perform research, development, and manufacturing of targeted anti-cancer therapies. They also provide pipeline/clinical trials news publications, YouTube content, and careers information.
Q5: What is the name of EnGeneIC's proprietary nanocell platform?
A5: The name of EnGeneIC's proprietary nanocell platform is EDV (EnGeneIC Dream Vector), which is a first-in-class cyto-immunotherapy platform targeting tumors directly and leveraging patients' own immune systems.
Q6: Who has partnered with EnGeneIC to advance their cancer treatment technology?
A6: BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), has partnered with EnGeneIC for a project including technology transfer, process scale-up, and GMP batch manufacture of EnGeneIC's proprietary 'EnGeneIC Dream Vector' (EDV) nanocells.
Q7: What is the name of the Singapore Institute that has forged a strategic partnership with EnGeneIC?
A7: The Singapore Institute of Advanced Medicine Holdings (SAM) has forged a strategic partnership with EnGeneIC, along with Singapore Medical Incorporation (SMI), to revolutionize cancer treatment and accelerate clinical development, manufacture, and commercialization of EnGeneIC's proprietary technology.
Q8: What is the location where EnGeneIC plans to progress its clinical trial programs?
A8: EnGeneIC plans to progress its clinical trial programs in Australia and the USA, with significant new funding provided by their partnerships.
A1: The address of EnGeneIC's Sydney office is Level 4, Building 53, 11 Julius Avenue, North Ryde, NSW Australia 2113.
Q2: What type of products does EnGeneIC develop and manufacture?
A2: EnGeneIC develops and manufactures targeted anti-cancer therapies using its proprietary EDV nanocell platform for the delivery of chemotherapeutics and functional nucleic acids in cancer.
Q3: In which industry is EnGeneIC primarily involved?
A3: EnGeneIC is primarily involved in the biopharmaceutical industry, specifically focused on developing treatments for cancer.
Q4: What services does EnGeneIC offer?
A4: While the provided text does not explicitly state all services offered by EnGeneIC, it mentions that they perform research, development, and manufacturing of targeted anti-cancer therapies. They also provide pipeline/clinical trials news publications, YouTube content, and careers information.
Q5: What is the name of EnGeneIC's proprietary nanocell platform?
A5: The name of EnGeneIC's proprietary nanocell platform is EDV (EnGeneIC Dream Vector), which is a first-in-class cyto-immunotherapy platform targeting tumors directly and leveraging patients' own immune systems.
Q6: Who has partnered with EnGeneIC to advance their cancer treatment technology?
A6: BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), has partnered with EnGeneIC for a project including technology transfer, process scale-up, and GMP batch manufacture of EnGeneIC's proprietary 'EnGeneIC Dream Vector' (EDV) nanocells.
Q7: What is the name of the Singapore Institute that has forged a strategic partnership with EnGeneIC?
A7: The Singapore Institute of Advanced Medicine Holdings (SAM) has forged a strategic partnership with EnGeneIC, along with Singapore Medical Incorporation (SMI), to revolutionize cancer treatment and accelerate clinical development, manufacture, and commercialization of EnGeneIC's proprietary technology.
Q8: What is the location where EnGeneIC plans to progress its clinical trial programs?
A8: EnGeneIC plans to progress its clinical trial programs in Australia and the USA, with significant new funding provided by their partnerships.
Customs Data
As a purchaser
As a Supplier
Get the Whole details
Contact
Total found ??? Contacts
All
Boss
Management
Procurement
Other
Get the Whole details
